Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

CLICK HERE FOR CME CREDIT

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS,which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology Chairman of the Department of Cardiology Heartcenter of the University Medical Center Nijmegen, The Netherlands